Although AstraZeneca, Daiichi Sankyo and England’s drug cost watchdog have spent months trying to hash out a fair price for Enhertu, the trio’s best efforts—and even the intervention of the U.K.’s new ...

Enhertu, a targeted cancer therapy from partners AstraZeneca and Daiichi Sankyo, may now be used as a first-line treatment for advanced cases of breast cancer, making it the first new approved ...

Remember the groundbreaking HER2-low data for AstraZeneca and Daiichi Sankyo’s Enhertu that garnered a standing ovation at the ASCO meeting last year? England’s cost watchdog now thinks the med’s ...

For women with a specific type of breast cancer known as HER2-positive (HER2+), any residual (leftover) disease after primary treatment with surgery, chemotherapy, and/or targeted drugs means the risk ...